1Fedak PW, Verma S, Weisel RD, et al. Cardiac remodeling and failure : from molecules to man[ J]. Cardiovase Patho1,2005,14 (1) :1-11.
2Fichtlscherer S,De Rosa S,Fox H,et al. Circulating microRNAs in patients with coronary artery disease[J]. Circulation Res,2010,107(5) :677-684.
3van Rooij E, Sutherland LB, Qi X, et al. Control of stress-dependent cardiac growth and gene expression by a microRNA[ J]. Science,2007, 316(5824) :575-579.
4Callis TE, Pandya K, Seok HY, et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice [ J ]. J Clin Invest, 2009, 119(9) :2772-2786.
5Sabbah HN. Apoptotic cell death in heart failure [ J ]. Cardious Res, 2000,45(3) :704-712.
6Sayed D, He M, Hong C, et al. MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotie effects via suppression of fas ligand [ J]. J Biol Chem,2010,285 (26) :20281-20290.
7Cheng Y, Liu X, Zhang S, et al. MicroRNA-21 protects against the H2O2-induced injury on cardiac myocytes via its target gene PDCIM [J]. J Mol Cell Cardio1,2009,47 ( 1 ) :5-14.
8Web CS, Bonnema DD, Ahmed SH, et al. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction : relation to left ventricular remodeling [ J ]. Circulation, 2006, 114 (10) : 1020-1027.
9Li M J, Huang CX, Okello E, et al. Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology [J]. Can J Cardiol,2009,25(9) :523-526.
10Morita H, Khanal S, Rastogi S. et al. Selective matrix metalloproteinase inhibition attenuates progression of left vcntricular dysfunction and remodeling in dogs with chronic heart failure [ J ]. Am J Physiol Heart Circ Physio1,2006,290 (6) : H2522-H2527.
3Suffrddini, Rupprecht HJ, Blankenbegs, et al. The cardiovascular response of normal humans to the administration of endotoxin [J]. N EnglJ Med, 1989, 321: 280-287.
4Torre-Amione G, Torre AG, Lamendola C, et al Expression and functional significance of tumor necrosis factor receptors in human myocardium [J]. Circulation, 1995, 92: 1487-1493.
5Yokoyama T, Dorland R, Kirschhof CJ, et al. Cellular basis for the negative inotropic effects of tumor necrosis factor alpha in the adult mamalian heart[J]. J Clin Invest, 1993, 92 : 2303-2312.
6Mahmoud Suleiman, Rania Khatib, Yoran Agmon, et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of actue myocardial infarction [J]. J Am Coll Cardiol, 2006, 47: 962-968.
7Kenneth D. C-reactive protein in ischaemic cardiomyopathy: assessing vascular risk in heart failure [J]. European Heart Journal, 2005, 26: 2218-2219.
8Fichtlscherer S, Rosenberer G, Dirk H, et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in pa- tients with coronary artery disease [J]. Circulation, 2000, 102, 1000-1006.
9Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? [J]. Lancet, 1997, 349: 1391-1392.
10Bhagat K, Vallance P. Inflammatory cytokines impair endothelium dependent dilation in human veins in vivo [J]. Circulation, 1997, 96:3042-3047.
